×
About 1,460 results

ALLMedicine Prolactinoma Center

Research & Reviews  709 results

Predictors of dopamine agonist resistance in prolactinoma patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236128
BMC Endocrine Disorders; Vermeulen E, D'Haens J et. al.

May 20th, 2020 - Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we tho...

Ki-67 and Clinical Correlations in Patients with Resistant Prolactinomas.
https://www.ncbi.nlm.nih.gov/pubmed/32366557
Annals of Clinical and Laboratory Science; Lu C, Liu Y et. al.

May 4th, 2020 - Drug resistance is the main limitation for dopamine agonist therapy with prolactinoma. Transsphenoidal surgery is an additional operation that circumvents this limitation. To characterize distinctive clinical features of resistant prolactinoma in ...

Prolactinoma
https://emedicine.medscape.com/article/124634-overview

Apr 20th, 2020 - Practice Essentials Prolactinomas, benign lesions that produce the hormone prolactin, are the most common hormone-secreting pituitary tumors. [1] Causing hyperprolactinemia, prolactinomas can reduce estrogen levels in women and testosterone concen...

Prolactinoma 
https://emedicine.medscape.com/article/124634-print

Apr 20th, 2020 - Practice Essentials Prolactinomas, benign lesions that produce the hormone prolactin, are the most common hormone-secreting pituitary tumors.[1] Causing hyperprolactinemia, prolactinomas can reduce estrogen levels in women and testosterone concent...

Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuatin...
https://doi.org/10.1016/j.jep.2020.112862
Journal of Ethnopharmacology; Huang X, Ren L et. al.

Apr 15th, 2020 - Paeoniflorin, a prominent component in some Chinese formulas for hyperprolactinemia-associated disorders, has been found to inhibit prolactin secretion in prolactinoma cells. To examine the efficacy of paeoniflorin on hyperprolactinemia and the un...

see more →

Clinicaltrials.gov  731 results

Predictors of dopamine agonist resistance in prolactinoma patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236128
BMC Endocrine Disorders; Vermeulen E, D'Haens J et. al.

May 20th, 2020 - Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we tho...

Ki-67 and Clinical Correlations in Patients with Resistant Prolactinomas.
https://www.ncbi.nlm.nih.gov/pubmed/32366557
Annals of Clinical and Laboratory Science; Lu C, Liu Y et. al.

May 4th, 2020 - Drug resistance is the main limitation for dopamine agonist therapy with prolactinoma. Transsphenoidal surgery is an additional operation that circumvents this limitation. To characterize distinctive clinical features of resistant prolactinoma in ...

Prolactinoma
https://emedicine.medscape.com/article/124634-overview

Apr 20th, 2020 - Practice Essentials Prolactinomas, benign lesions that produce the hormone prolactin, are the most common hormone-secreting pituitary tumors. [1] Causing hyperprolactinemia, prolactinomas can reduce estrogen levels in women and testosterone concen...

Prolactinoma 
https://emedicine.medscape.com/article/124634-print

Apr 20th, 2020 - Practice Essentials Prolactinomas, benign lesions that produce the hormone prolactin, are the most common hormone-secreting pituitary tumors.[1] Causing hyperprolactinemia, prolactinomas can reduce estrogen levels in women and testosterone concent...

Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuatin...
https://doi.org/10.1016/j.jep.2020.112862
Journal of Ethnopharmacology; Huang X, Ren L et. al.

Apr 15th, 2020 - Paeoniflorin, a prominent component in some Chinese formulas for hyperprolactinemia-associated disorders, has been found to inhibit prolactin secretion in prolactinoma cells. To examine the efficacy of paeoniflorin on hyperprolactinemia and the un...

see more →

News  15 results

Prolactin, the pituitary, and pregnancy: Where’s the balance?
https://www.mdedge.com/familymedicine/article/164370/pituitary-thyroid-adrenal-disorders/prolactin-pituitary-and-pregnancy/page/0/3
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

Pituitary Incidentaloma
https://www.mdedge.com/clinicianreviews/article/96669/endocrinology/pituitary-incidentaloma/page/0/1

Jan 26th, 2015 - SHOULD AN ASYMPTOMATIC PATIENT BE EVALUATED FURTHER? Endocrine Society guidelines2 recommend that all patients with pituitary incidentaloma, with or without symptoms, should undergo a complete history and physical examination and laboratory evalua.

Prolactinoma: A Case Study
https://www.mdedge.com/clinicianreviews/article/72153/endocrinology/prolactinoma-case-study/page/0/1

Nov 1st, 2011 - Dopamine agonists are approximately 80% to 90% effective in decreasing prolactin levels and reducing tumor size in microadenomas and 60% to 70% in macroadenomas. The major drawback of using medication is that it does not always provide permanent r.

Endocrine Society Releases Guidelines on Pituitary Incidentalomas
https://www.mdedge.com/internalmedicine/article/34059/endocrinology/endocrine-society-releases-guidelines-pituitary
Elizabeth Mechcatie

Apr 20th, 2011 - Surgical treatment of a pituitary incidentaloma is recommended when the lesion is causing a visual field deficit or other visual abnormalities, such as ophthalmoplegia "or neurological compromise," according to evidence-based clinical practice gui.

Cabergoline Withdrawal Safe in Some Patients With Prolactinoma Responding to Treatment
https://www.medscape.com/viewarticle/464715

Nov 18th, 2003 - Nov. 19, 2003 -- Withdrawal of cabergoline appears to be safe if no evidence of prolactinoma is present or tumor size has decreased by at least 50%, according to the findings of a new observational, prospective study. According to the researchers,...

see more →

Patient Education  5 results see all →